Abstract
Study design. *Patients randomized after the date of DIL who were unable to receive feladilimab/placebo were excluded from the mITT population but included in the safety population; †more than one reason could be selected; AE, adverse event; DIL, Dear Investigator Letter; ITT, intention to treat; mITT, modified ITT.